Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 17Multiple Myeloma 12Ovarian Neoplasms 9Recurrence 8Lymphoma, B-Cell 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma 7Hodgkin Disease 7Burkitt Lymphoma 7Colorectal Neoplasms 6Myeloproliferative Disorders 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Biphenotypic, Acute 5Stomach Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Leukemia, B-Cell 3

Interventions

Cyclophosphamide 2pembrolizumab 1fludarabine 1duvelisib 1Vincristine 1Prednisone 1Etoposide 1Doxorubicin 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × fludarabine × 30 days × Clear all
NCT07055477 2026-05-22

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
60 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡